Karah Herdman Parschauer

CIK: 0001677455

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (52.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)9 (47.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RARE

Ultragenyx Pharmaceutical Inc.

Officer

TNYA

Tenaya Therapeutics, Inc.

Director

EOLS

Evolus, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (19 total)

RARE
Ultragenyx Pharmaceutical Inc.
Aug 3, 2026
Sale(S)
Direct
1.9K shares at avg. $24.92$47K
RARE
Ultragenyx Pharmaceutical Inc.
Jun 15, 2026
Sale(S)
Direct
1.9K shares at avg. $24.62$47K
TNYA
Tenaya Therapeutics, Inc.
May 28, 2026
Award(A)
Stock Option (Right to buy)
Direct
120K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Apr 16, 2026
Award(A)
Direct
28.9K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 10, 2026
Sale(S)
Direct
3.5K shares at avg. $22.67$80K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 6, 2026
Sale(S)
Direct
6K shares at avg. $21.40$129K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 2, 2026
Sale(S)
Direct
8.1K shares at avg. $22.80$185K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2026
Award(A)
Direct
11.1K shares-
EOLS
Evolus, Inc.
Feb 17, 2026
Award(A)
Direct
45.6K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Sep 12, 2025
Sale(S)
Direct
2.5K shares at avg. $31.17$76K
TNYA
Tenaya Therapeutics, Inc.
May 29, 2025
Award(A)
Stock Option (Right to buy)
Direct
107.4K shares-
EOLS
Evolus, Inc.
Mar 12, 2025
Sale(S)
Direct
12.9K shares at avg. $12.99$167K
EOLS
Evolus, Inc.
Mar 7, 2025
Award(A)
Direct
7.4K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 3, 2025
Sale(S)
Direct
12.8K shares at avg. $42.10$541K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2025
Award(A)
Direct
18.4K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2025
Award(A)
Direct
14.5K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Feb 27, 2025
Sale(S)
Direct
760 shares at avg. $42.75$32K
RARE
Ultragenyx Pharmaceutical Inc.
Feb 27, 2025
Sale(S)
Direct
2.2K shares at avg. $42.93$96K
TNYA
Tenaya Therapeutics, Inc.
Oct 18, 2024
Award(A)
Stock Option (Right to buy)
Direct
34K shares-

		Type	Shares	Price		Ownership
Aug 3, 2026	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	1,900	$24.92	$47,348	Direct
Jun 15, 2026	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	1,899	$24.62	$46,753	Direct
May 28, 2026	TNYA Tenaya Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	120,000	-	-	Direct
Apr 16, 2026	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	28,895	-	$0	Direct
Mar 10, 2026	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	3,508	$22.67	$79,526	Direct
Mar 6, 2026	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	6,018	$21.40	$128,785	Direct
Mar 2, 2026	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	8,135	$22.80	$185,478	Direct
Mar 1, 2026	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	11,137	-	$0	Direct
Feb 17, 2026	EOLS Evolus, Inc.	Award(A)	45,559	-	$0	Direct
Sep 12, 2025	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	2,450	$31.17	$76,367	Direct
May 29, 2025	TNYA Tenaya Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	107,400	-	-	Direct
Mar 12, 2025	EOLS Evolus, Inc.	Sale(S)	12,888	$12.99	$167,465	Direct
Mar 7, 2025	EOLS Evolus, Inc.	Award(A)	7,364	-	-	Direct
Mar 3, 2025	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	12,846	$42.10	$540,817	Direct
Mar 1, 2025	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	18,443	-	-	Direct
Mar 1, 2025	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	14,494	-	-	Direct
Feb 27, 2025	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	760	$42.75	$32,490	Direct
Feb 27, 2025	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	2,230	$42.93	$95,734	Direct
Oct 18, 2024	TNYA Tenaya Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	34,000	-	-	Direct

1-19 of 19 transactions

About Parschauer Karah Herdman

Parschauer Karah Herdman (SEC CIK 0001677455) files insider reports with the SEC as EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc. (RARE), Director of Tenaya Therapeutics, Inc. (TNYA) and Director of Evolus, Inc. (EOLS).

Signal8 holds 14 ownership filings by Parschauer Karah Herdman, all Form 4s, filed between Oct 21, 2024 and Aug 4, 2026. Those filings report 19 transactions, from Oct 18, 2024 to Aug 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Parschauer Karah Herdman's filings is in NOVATO, CA.

Recent filings by Parschauer Karah Herdman

Aug 3, 2026: Open-market sale of RARE shares (Form 4, code S).
Jun 15, 2026: Open-market sale of RARE shares (Form 4, code S).
May 28, 2026: Grant or award of TNYA derivative securities (Form 4, code A).
Apr 16, 2026: Grant or award of RARE shares (Form 4, code A).
Mar 10, 2026: Open-market sale of RARE shares (Form 4, code S).

Other insiders filing for Ultragenyx Pharmaceutical Inc. (RARE)

Horn Howard, Chief Financial Officer
Huizenga Theodore Alan, SVP, Chief Accounting Officer
Sanders Corazon (Corsee) D., Director
Fust Matthew K, Director
SULIMAN SHEHNAAZ, Director
Ray Amrit, Director

How to read Form 4 transaction codes